Research
Key immune driver of pancreatic cancer points to combination treatment for slowing progression
The Brief
- Researchers at MD Anderson Cancer Center report that the inflammatory protein IL-18 helps pancreatic tumours grow and evade the immune system.
- The findings identify IL-18 as a potential therapeutic target for pancreatic cancer.
- The story points to a combination treatment approach for slowing disease progression.
Why it matters
It identifies a specific immune signalling protein as a possible drug target in pancreatic cancer, a disease with limited treatment options, which may guide future combination therapy research.
Who’s affected
- pancreatic cancer researchers
- oncology clinicians and drug developers
- #pancreatic cancer
- #il-18
- #tumor immunology
- #combination therapy
- #cancer research
Researchers from The University of Texas MD Anderson Cancer Center have discovered that the IL-18 inflammatory protein helps pancreatic tumors grow and evade the immune system, highlighting its potential as a therapeutic target for pancreatic cancer.